glp 1 agonist fda approval The New Weight Management Meds Oral semaglutide (Rybelsus) is the
Description
The weight loss induced by liraglutide at 3 mg is typically in the range of 510% after 52 wk of treatment of non-diabetic obese patients [895]
Available from: 147

Both the FDA and the European Medicines Agency are also now considering the approval of semaglutide for the treatment of chronic kidney diseases in patients with type 2 diabetes (Manalac, June 2024
Diabetes Care 27(7):15911597

2025 Mar 6;135(9):e188314

With ongoing advancements in biologic drug development and more investment in biopharmaceutical pipelines, this sector is expected to grow in the future
